Interim or End of Treatment FGD-PET Complete Response Does Not Have Adequate Predictive Value in Mature T/NK Cell Lymphoma
Tatyana Feldman(Hackensack University Medical Center), André Goy(Hackensack University Medical Center), Lori A. Leslie(Hackensack University Medical Center), Patrick Toth(Hackensack University Medical Center), Xiao Yan Yang(Hackensack Meridian Health), Alan P Skarbnik(Novant Health), Pritish K. Bhattacharyya(Hackensack University Medical Center), Ricardo Parrondo(Jacksonville College), David Panush(Hackensack University Medical Center), Sejal Kothadia(Rutgers, The State University of New Jersey), Veronica Mariotti(Moffitt Cancer Center), Larysa Sanchez(Icahn School of Medicine at Mount Sinai), Zhen Wang(Mayo Clinic), Anthony R. Mato(University of Pennsylvania), Miguel Gonzalez(Rutgers, The State University of New Jersey), Themba Nyirenda(Hackensack University Medical Center), Kar Fai Chow(Hackensack Meridian Health), Ewelina Protomastro(Hackensack University Medical Center)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Patient engagement in research: a systematic review
|BMC Health Services Research|2014|1.8k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k